StoryFunding
Iambic Therapeutics files for $100-150M IPO on Nasdaq; AI-native drug discovery platform advances IAM1363 to registrational trials
Iambic Therapeutics filed its Form S-1 registration statement for an initial public offering on Nasdaq under the ticker IAM, seeking $100-150M in gross proceeds. The San Diego-based company leverages AI and automated chemistry to discover drugs; IAM1363, its brain-penetrating HER2 inhibitor, is in Phase 1/1b trials with registrational studies planned for 2027.